Not logged in Share Save
Share Save
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines Razumovskaya, Alexandra; Silkina, Mariia; Poloznikov, Andrey; Kulagin, Timur; Raigorodskaya, Maria; Gorban, Nina; Kudryavtseva, Anna; Fedorova, Maria; Alekseev, Boris; Tonevitsky, Alexander; Nikulin, Sergey Share Save
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis Gomez-Veiga, Francisco; Szmulewitz, Russell Z.; Holzbeierlein, Jeffrey; Azad, Arun A.; Iguchi, Taro; Villers, Arnauld; Alcaraz, Antonio; Alekseev, Boris; Shore, Neal D.; Rosbrook, Brad; Zohren, Fabian; Ma, Jie; Haas, Gabriel P.; Stenzl, Arnulf; Armstrong, Andrew J. Share Save
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study Cicin, Irfan; Plimack, Elizabeth R.; Gurney, Howard; Leibowitz, Raya; Alekseev, Boris Y.; Parnis, Francis X.; Peer, Avivit; Necchi, Andrea; Bellmunt, Joaquim; Nishiyama, Hiroyuki; Clark, Jason; Munteanu, Mihaela; Kataria, Ritesh; Jia, Calvin; Powles, Thomas; Sternberg, Cora N. Share Save
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study Necchi, Andrea; van der Heijden, Michiel S.; Trukhin, Dmytro; Peer, Avivit; Gurney, Howard; Alekseev, Boris Y.; Parnis, Francis X.; Leibowitz, Raya; De Santis, Maria; Grivas, Petros; Clark, Jason; Munteanu, Mihaela; Kataria, Ritesh; Jia, Calvin; Balar, Arjun V.; de Wit, Ronald Share Save
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study[Eur Urol 84(5) (2023) 449-454] Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; McDermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Molife, L. Rhoda; Li, Chenxiang; Perini, Rodolfo; Bedke, Jens; Rini, Brian I. Share Save
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma Grande, Enrique; Bamias, Aristotelis; Galsky, Matthew D.; Kikuchi, Eiji; Davis, Ian D.; Arranz, Jose Angel; Kalebasty, Arash Rezazadeh; del Muro, Xavier Garcia; Park, Se Hoon; De Giorgi, Ugo; Alekseev, Boris; Mencinger, Marina; Izumi, Kouji; Puente, Javier; Li, Jian-Ri; Bernhard, Sandrine; Nicholas, Alan; Telliez, Julie; De Santis, Maria Share Save
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; Mcdermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Rini, Brian I. Share Save
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study ( vol 84 , pg , 449 , 2023) Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Poulioti, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; McDermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Riniu, Brian I. Share Save
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES Armstrong, Andrew J.; Iguchi, Taro; Azad, Arun A.; Villers, Arnauld; Alekseev, Boris; Petrylak, Daniel P.; Szmulewitz, Russell Z.; Alcaraz, Antonio; Shore, Neal D.; Holzbeierlein, Jeffrey; Gomez-Veiga, Francisco; Rosbrook, Brad; Zohren, Fabian; Haas, Gabriel P.; Gourgiotti, Georgia; El-Chaar, Nader; Stenzl, Arnulf Share Save
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial Boegemann, Martin; Shore, Neal D.; Smith, Matthew R.; Tammela, Teuvo L. J.; Ulys, Albertas; Vjaters, Egils; Polyakov, Sergey; Jievaltas, Mindaugas; Luz, Murilo; Alekseev, Boris; Lebret, Thierry; Schostak, Martin; Verholen, Frank; Le Berre, Marie-Aude; Srinivasan, Shankar; Ortiz, Jorge; Mohamed, Ateesha F.; Sarapohja, Toni; Fizazi, Karim Share Save
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial (vol 83, pg 212, 2023) Boegemann, Martin; Shore, Neal D.; Smith, Matthew R.; Tammela, Teuvo L. J.; Ulys, Albertas; Vjaters, Egils; Polyakov, Sergey; Jievaltas, Mindaugas; Luz, Murilo; Alekseev, Boris; Lebret, Thierry; Schostak, Martin; Verholen, Frank; Le Berre, Marie-Aude; Srinivasan, Shankar; Ortiz, Jorge; Mohamed, Ateesha F.; Sarapohja, Toni; Fizazi, Karim Share Save
Share Save
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial Pal, Sumanta K.; Puente, Javier; Heng, Daniel Y. C.; Glen, Hilary; Koralewski, Piotr; Stroyakovskiy, Daniil; Alekseev, Boris; Parnis, Francis; Castellano, Daniel; Ciuleanu, Tudor; Lee, Jae Lyun; Sunela, Kaisa; O'Hara, Karen; Binder, Terri A.; Peng, Lixian; Smith, Alan D.; Rha, Sun Young Share Save
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial Rini, Brian I.; Atkins, Michael B.; Plimack, Elizabeth R.; Soulieres, Denis; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Alekseev, Boris; Melichar, Bohuslav; Shparyk, Yaroslav; Kondoh, Chihiro; Langiewicz, Przemyslaw; Wood, Lori A.; Hammers, Hans; Silber, Cynthia G.; Haber, Barbara; Jensen, Erin; Chen, Mei; Powles, Thomas Share Save
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer Smith, Matthew R.; Hussain, Maha; Saad, Fred; Fizazi, Karim; Sternberg, Cora N.; Crawford, E. David; Kopyltsov, Evgeny; Park, Chandler H.; Alekseev, Boris; Montesa-Pino, Alvaro; Ye, Dingwei; Parnis, Francis; Cruz, Felipe; Tammela, Teuvo L. J.; Suzuki, Hiroyoshi; Utriainen, Tapio; Fu, Cheng; Uemura, Motohide; Mendez-Vidal, Maria J.; Maughan, Benjamin L.; Joensuu, Heikki; Thiele, Silke; Li, Rui; Kuss, Iris; Tombal, Bertrand Share Save
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial Powles, Thomas; Yuen, Kobe C.; Gillessen, Silke; Kadel, Edward E.; Rathkopf, Dana; Matsubara, Nobuaki; Drake, Charles G.; Fizazi, Karim; Piulats, Josep M.; Wysocki, Piotr J.; Buchschacher, Gary L., Jr.; Alekseev, Boris; Mellado, Begona; Karaszewska, Boguslawa; Doss, Jennifer F.; Rasuo, Grozdana; Datye, Asim; Mariathasan, Sanjeev; Williams, Patrick; Sweeney, Christopher J. Share Save
Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non-clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B Lee, J-L.; McDermott, D. F.; Ziobro, M.; Suarez, C.; Langiewicz, P.; Matveev, V. B.; Wiechno, P.; Gafanov, R.; Tomczak, P.; Pouliot, F.; Donskov, F.; Alekseev, B. Y.; Shin, S. J.; Bjarnason, G. A.; Castellano, D.; Liu, H.; Burgents, J.; Rodriguez-Lopez, K.; Atkins, M. B. Share Save
Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) Armstrong, A. J.; Iguchi, T.; Azad, A. A.; Szmulewitz, R. Z.; Holzbeierlein, J.; Villers, A.; Alcaraz, A.; Alekseev, B. Y.; Shore, N. D.; Petrylak, D. P.; Rosbrook, B.; Zohren, F.; Yamada, S.; Haas, G. P.; Stenzl, A. Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
